Likarda Receives $4 Million Series A Funding from Werth Family Investment Associates
NMBio preferred provider and cutting-edge biotech research laboratory, Likarda, has received $4,000,000 in Series A funding from Werth Family Investment Associates, bringing the promise of future diabetes treatment options to dogs and cats. Likarda is the leading regenerative medicine company for companion animals. They have discovered—and are commercializing—a better way to manage diabetes in dogs and cats. Their insulin-producing cell clusters, called the Kanslet™, can be infused into animals with diabetes. The process allows veterinarians to offer a minimally invasive, cost-effective answer to pet owners battling the burden of diabetes in dogs and cats.
With an estimated 1 in 100 dogs and cats contracting diabetes in their lifetime, nearly 1.5 million pets will suffer from diabetes at some point. Currently, the only option for treatment is twice daily insulin injections, placing enormous stress on pets and their owners. Through years of development and working with various partners, Likarda is in the process of bringing islet transplants to dogs. The microencapsulated islets (the insulin-producing cells of the body) are transplanted via injection into the belly of a diabetic dog, removing the need for twice daily insulin injections. The additional resources provided by the investment allow Likarda to scale the project from hundreds of animals to thousands in the treatment of diabetic pets. The clinical research program is being finalized and is expected to launch by the end of 2017.
In addition to pioneering work in the animal health arena, Likarda — http://likarda.com/ — is a world-class contract research organization (CRO), supporting start-up companies and science entrepreneurs through large pharmaceutical and nutraceutical companies. Likarda uses a proprietary cell culture system to create three-dimensional cell clusters, or miniaturized organs. This system has applications in markets ranging from drug discovery and development to cell-based transplantation and regenerative medicine. The technology and its ability to scale gives pharmaceutical companies a way to test new drug compounds on human 3D cell clusters, providing a better prediction of how the drugs will work in the body. Please note, Likarda offers NMBio members a 5 percent discount on all its services.